Navigation Links
ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008
Date:1/4/2008

DENVER, Jan. 4 /PRNewswire/ -- ARCA Discovery Inc., a privately held biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced Richard B. Brewer, President and Chief Executive Officer, will present at the 26th Annual JPMorgan Healthcare Conference on Tuesday, January 8 at 2:00 PM PT.

The JPMorgan Healthcare Conference will be held January 7-10, 2008 at the Westin St. Francis in San Francisco, California.

About ARCA Discovery, Inc.

ARCA Discovery, Inc. is a privately-held biopharmaceutical company based in Denver, Colorado developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company's first product is bucindolol, a next generation beta-blocker for chronic heart failure, which promises to be the first personalized, genetically-targeted cardiovascular therapy. ARCA plans to file for FDA approval of bucindolol in 2008, and to leverage its platform to develop other pharmacogenetic therapies for cardiovascular diseases. The Company recently closed a Series B round of $18 million, led by new investors Skyline Ventures and InterWest Partners. ARCA completed a $15 million Series A round in 2006 led by Atlas Venture and Boulder Ventures, which also participated in the Series B round.

About Bucindolol

ARCA has exclusive worldwide rights to bucindolol, a next generation beta-blocker for chronic heart failure. ARCA's cardiovascular platform combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development, in a unique approach that enables the efficient identification of pharmacogenetic targets. Applying this approach to bucindolol, ARCA has identified pathways affecting bucindolol response that are modulated by common genetic variations. This discovery is supported by substantial Phase 3 data, and will allow a physician to determine whether bucindolol is the right therapy for a patient with a simple genetic test. ARCA has partnered with Laboratory Corporation of America to develop the bucindolol genetic test. Prescribed by using this test, bucindolol could have significant advantages for many chronic heart failure patients. With experience in commercializing cardiovascular products, ARCA plans to market bucindolol in the U.S. through its own sales force.


'/>"/>
SOURCE ARCA Discovery Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
2. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
3. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
5. AutoGenomics Invited to Present at the JPMorgan Healthcare Conference
6. Thermage, Inc. to Present at the 10th Annual Needham & Company Growth Conference
7. Advanced Life Sciences to Present at Biodefense Session of 26th Annual JPMorgan Healthcare Conference
8. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
9. Xoft to Present at the 26th Annual JPMorgan Healthcare Conference
10. Danaher to Present at J.P. Morgan Healthcare Conference
11. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... Phoenix, Arizona (PRWEB) , ... October 09, 2017 ... ... of Kindred, a four-tiered line of medical marijuana products targeting the needs of ... production and packaging of Kindred takes place in Phoenix, Arizona. , As operators ...
Breaking Biology Technology:
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):